摘要:
The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.
摘要翻译:本发明涉及短链SRL醇脱氢酶(DHRS4,SEQ ID NO:1)及其肽作为体液生物标志物用于诊断检测和预后的用途,并且还监测脓毒性炎症的过程和治疗, 感染。
摘要:
Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
摘要翻译:用于早期诊断和诊断的方法,用于预测和评估炎性疾病和感染,特别是脓毒症样全身感染和阿尔茨海默氏病的严重性和治疗伴随监测,其中蛋白质LASP- 1(SEQ ID NO:1)或蛋白质LAP-1(SEQ ID NO:16)或这些蛋白质之一的游离和/或蛋白结合形式的免疫反应性片段优选作为免疫反应性 生物流体或任选的组织样品,并且根据存在和/或数量的炎症性疾病或感染的治疗的存在,预期进程,严重程度或成功性得出结论 的蛋白质。
摘要:
Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
摘要:
Use of calcineurin B homologous protein (CHP) from body fluids or body tissues as a marker peptide for diagnosis, for prognosis and for monitoring the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
摘要:
In a competitive receptor binding assay for detecting TSH-receptor auto-antibodies in a biological sample, the sample is reacted in a reaction mixture which contains (i) a TSH-receptor or TSH-receptor preparation; (ii) a primary competitor, for example labelled TSH; and (iii) an agent for separating a complex composed of the TSH-receptor and the elements bound thereto of the reaction mixture from the liquid phase. According to the invention, the reaction is carried out in the presence of at least one monoclonal or polyclonal antibody specific against a partial peptide sequence of the TSH eceptor. This specific antibody is used to immobilize a complex of TSH-receptor and primary competitor and/or as secondary competitor for another part of the TSH-receptor auto-antibodies expected in a sample. The primary or secondary competitors are or can be selectively labelled.
摘要:
Method for the determination of an analyte in a volume of a fluid sample, in particular of anti-TSH receptor autoantibodies in a patient serum, in which one or more determination reagent(s) which contains or which containa) a predetermined amount of a binder (B) for the analyte (A) and b) a predetermined amount of a competitor (K) which is likewise bound by the binder (B), in such a way that the extent of its binding to the binder (B) is correlated with the simultaneous presence of the analyte (A) and/or its amount in the sample, the competitor (K) being labelled, or being capable of being labelled, with a label which permits its qualitative and/or quantitative determination, is or are added to the sample with the formation of a liquid reaction mixture, wherein c) the liquid reaction mixture is reacted simultaneously or subsequently with a solid phase to which a substance (Imm) for the selective immobilization of the amount of competitor (K) not bound to the binder (B) is bound, and optionally with a labelled reactant (Label) for the immobilized competitor (K), and, after a quantitative separation of the solid phase from the liquid reaction mixture, the amount of the competitor (K) bound to the solid phase is determined in a manner known per se by means of physical and/or chemical detection of the label bound to said competitor, and the determined amount of said competitor (K) is correlated with the presence and/or amount of the analyte (A) in the original sample.
摘要:
The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.
摘要:
The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps: a) Preparation of a reversible binding partner 1 that is immobilized on a solid phase, to which an analyte binder is reversibly bonded via a reversible binding partner 2 that is bonded to the analyte binder, whereby the analyte binder is immobilized by binding between the reversible binding partners 1 and 2, b) Addition of the biological sample and binding of the analyte to the reversible immobilized analyte binder in the case that the biological sample contains the analytes, c) Separation of the biological sample, d) Addition of a dissolving buffer, which dissolves the binding between the reversible binding partners 1 and 2, whereby the binding of the analyte to the analyte binder remains optional, and e) Detection of the analyte in the dissolving buffer in the case that the biological sample contains the analytes and determination of the absence of the analyte in the case that the biological sample does not contain the analytes, respectively.
摘要:
The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.
摘要:
The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method.